Detalhe da pesquisa
1.
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
Nature;
565(7738): 234-239, 2019 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30568305
2.
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
J Neurooncol;
121(2): 297-302, 2015 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25338318
3.
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
J Clin Oncol;
41(36): 5524-5535, 2023 Dec 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37722087
4.
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.
Neuro Oncol;
24(1): 101-113, 2022 01 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34015129
5.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Clin Cancer Res;
27(4): 1048-1057, 2021 02 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33199490
6.
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
J Clin Oncol;
37(9): 741-750, 2019 03 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30715997
7.
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.
Clin Cancer Res;
24(19): 4643-4649, 2018 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29941486
8.
Health System Advance Care Planning Culture Change for High-Risk Patients: The Promise and Challenges of Engaging Providers, Patients, and Families in Systematic Advance Care Planning.
J Palliat Med;
20(4): 388-394, 2017 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27983894
9.
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Neuro Oncol;
17(6): 862-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25572329
10.
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Clin Cancer Res;
21(16): 3610-8, 2015 Aug 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25910950
11.
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Neurology;
84(3): 280-6, 2015 Jan 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25527270